Potential New Treatment for Alpha-1 Antitrypsin Deficiency

Trial Objective

Potential New Drug Alvelestat for AATDResearchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

Up to 5 months



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kristina Eliopoulos

Kristina Eliopoulos
303.270.2622

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health, University of Alabama at Birmingham


Request More Information

By completing this form, you agree to learn more about this study, see if you qualify and receive periodic updates about clinical research via email.


*
*
*
*